Voyager Therapeutics (VYGR) EBT Margin (2015 - 2026)

Voyager Therapeutics has disclosed EBT Margin across 12 years of filings, most recently posting 1076.86% for Q1 2026.

• EBT Margin for Q1 2026 came in at 1076.86%, down 60018.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 318.64% (down 19331.0% YoY), and the FY2025 annual result was 296.17%, down 21575.0% from the prior year.
• EBT Margin came in at 1076.86% for Q1 2026 at Voyager Therapeutics, down from 178.33% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 1523.23% in Q4 2022 to a low of 3239.97% in Q1 2022.
• The 5-year median for EBT Margin is 207.53% (2025), against an average of 498.53%.
• Across the five-year window, EBT Margin sank 284665 bps in 2022 and surged 332287 bps in 2023, its largest moves.
• Voyager Therapeutics' EBT Margin stood at 1523.23% in 2022, then sank by 96 bps to 63.5% in 2023, then tumbled by 947 bps to 538.06% in 2024, then soared by 67 bps to 178.33% in 2025, then slumped by 504 bps to 1076.86% in 2026.
• The last three EBT Margin figures came in at 1076.86% (Q1 2026), 178.33% (Q4 2025), and 207.53% (Q3 2025), per Business Quant data.